CDKN2A and prostate carcinoma: Indeed PSD/EFA6 shows robust activation of the Class I ARF, ARF1, when membranes are included in in vitro assays [41], and a preference for the Class I ARF GTPase ARF3, and not ARF6, in invasive prostate cancer cell lysates [42].